Treatment with the new drugs.

[Justasheet1]

Another article on novel agents. A positive take away. onclive.com/web-exclusives/...

Jeff

[AussieNeil Partner Administrator]

Thanks Jeff. As the article starts out "Non-chemotherapeutic regimens are poised to become the standard of care for patients with non-Hodgkin’s lymphoma (NHL), based on their safety profiles and effectiveness compared with traditional treatment options.

This transformation in care was initiated by the approvals of ibrutinib (Imbruvica) and idelalisib (Zydelig) for patients with chronic lymphocytic leukemia (CLL)..."

So clinical trials into CLL are now helping patients with other NHL's. As the article concludes: "It is an exciting time in B-cell malignancies."

Neil